Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment

Peng Tang,Gangfu Zheng,Congcong Xu,Nengfeng Yu,Jiaqi Du,Liqian Hu,Zhan Zhou,Yichun Zheng
DOI: https://doi.org/10.1097/md.0000000000037939
IF: 1.6
2024-05-19
Medicine
Abstract:Renal cell carcinoma (RCC) is one of the most prevalent malignancies in the world. Statistics show that 179,368 patients died from RCC-related causes and that 431,288 new cases of RCC were diagnosed globally in 2020. [ 1 ] The most typical histological subtype of RCC and the leading cause of death from RCC is clear cell renal cell carcinoma (ccRCC). [ 2 , 3 ] RCC was perhaps the exemplar of malignancies characterized by metabolic reprogramming, [ 4–8 ] which refers to glucose metabolism, [ 9–11 ] the tricarboxylic acid cycle, [ 12 , 13 ] lipid metabolism [ 14 , 15 ] and amino acid metabolism. [ 16 , 17 ] Therefore kidney cancer is referred to as a metabolic disease. Although primary localized ccRCC can be treated with surgical resection, the treatment of advanced ccRCC remains a clinical challenge as a result of having low radiation and susceptibility to adjuvant chemotherapy. [ 18 , 19 ] Immune checkpoint inhibitors (ICIs) have recently been shown to be beneficial in treating patients with metastatic renal cancer., [ 20 , 21 ] but death and morbidity rates are still high. [ 22 ] At present, there is a lack of biomarkers to determine the prognosis of ccRCC patients. Therefore, identifying biomarkers of ccRCC for early diagnosis and evaluation of prognosis is vital for the management and treatment of ccRCC patients.
medicine, general & internal
What problem does this paper attempt to address?